Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703177 | 0.87 | CHRNA7 (0.43) | CHRNA7SCD | |
| SCHEMBL4702524 | 0.86 | CHRNA7 (0.48) | CHRNA7 | |
| SCHEMBL4703053 | 0.82 | DYRK1A (0.43) | DYRK1BDYRK1ACLK1HASPINCHRNA7 | |
| SCHEMBL373015 | 0.82 | MKNK1 (0.56) | BRAFCHRNB2CHRNA4CHRNA7CYP2C9 | |
| SCHEMBL4700611 | 0.81 | KMO (0.52) | CHRNA7CYP11B2CYP11B1 | |
| SCHEMBL4701174 | 0.80 | MKNK1 (0.55) | CHRNA7CYP11B2 | |
| SCHEMBL4701391 | 0.80 | CHRNA7 (0.42) | CHRNA7CYP2C9 | |
| SCHEMBL4702396 | 0.79 | CHRNA7 (0.42) | CHRNA7 | |
| SCHEMBL4702987 | 0.78 | CHRNA7 (0.44) | CHRNA7 | |
| SCHEMBL4704002 | 0.78 | CHRNA7 (0.47) | CHRNA7SCDCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | claimed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | claimed |
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | CHRNA1, CHRNB1, CHRNA2 | BRAF 4304/4885DYRK1B 823/4885DYRK1A 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.